Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Moleculin Biotech, Inc. MBRX
$0.67
-$0.07 (-10.29%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
22471554.00000000
-
week52high
1.94
-
week52low
0.65
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.99515500
-
EPS
-1.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 17 окт 2019 г. | |
| Maxim Group | Buy | 14 ноя 2018 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KLEMP WALTER V | A | 409890 | 45000 | 25 ноя 2022 г. |
| KLEMP WALTER V | A | 364890 | 22500 | 21 ноя 2022 г. |
| KLEMP WALTER V | A | 342390 | 24742 | 17 ноя 2022 г. |
| KLEMP WALTER V | A | 317648 | 85213 | 16 ноя 2022 г. |
| KLEMP WALTER V | D | 1097941 | 13205 | 11 июл 2022 г. |
| KLEMP WALTER V | D | 232435 | 3215 | 11 июл 2022 г. |
| KLEMP WALTER V | A | 235650 | 13204 | 11 июл 2022 г. |
| KLEMP WALTER V | D | 1369941 | 13205 | 11 июл 2022 г. |
| KLEMP WALTER V | D | 1111145 | 14717 | 02 июл 2022 г. |
| KLEMP WALTER V | D | 222446 | 3584 | 02 июл 2022 г. |
Новостная лента
Moleculin Biotech, Inc. (MBRX) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 11:29
Moleculin Biotech, Inc. (NASDAQ:MBRX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Jenene Thomas - Investor Relations Walter Klemp - Chairman and Chief Executive Officer John Paul Waymack - Senior Chief Medical Officer Jonathan Foster - Executive Vice President and Chief Financial Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Jeff Jones - Oppenheimer Operator Hello and welcome to the Moleculin Biotech Q1 2023 Quarterly Update Conference Call and Webcast. [Operator Instructions] A question-and-answer session will follow the formal presentation.
MBRX Stock Earnings: Moleculin Biotech Misses EPS Estimates
InvestorPlace
11 мая 2023 г. в 08:04
Moleculin Biotech (NASDAQ: MBRX ) reported first quarter results for 2023. Moleculin Biotech reported a loss per share of 28 cents.
Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
PRNewsWire
04 мая 2023 г. в 08:35
HOUSTON , May 4, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it will report its financial results for the first quarter ended March 31, 2023, on Thursday, May 11, 2023. Moleculin management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET that same day.
Here's Why Moleculin Biotech, Inc. (MBRX) Looks Ripe for Bottom Fishing
Zacks Investment Research
24 апр 2023 г. в 11:25
Moleculin Biotech, Inc. (MBRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Moleculin Biotech, Inc. (MBRX) Upgraded to Buy: What Does It Mean for the Stock?
Zacks Investment Research
27 мар 2023 г. в 13:45
Moleculin Biotech, Inc. (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).